Can Immunic Inc’s (IMUX) hike of 9.29% in a week be considered a lucky break?

A new trading day began on Monday, with Immunic Inc (NASDAQ: IMUX) stock price up 5.20% from the previous day of trading, before settling in for the closing price of $0.73. IMUX’s price has ranged from $0.56 to $2.11 over the past 52 weeks.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

Annual sales at Healthcare sector company grew by 26.01% over the past five years. Meanwhile, its annual earnings per share averaged 28.99%. With a float of $92.55 million, this company’s outstanding shares have now reached $95.82 million.

Let’s look at the performance matrix of the company that is accounted for 91 employees. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.

Immunic Inc (IMUX) Insider and Institutional Ownership

As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Immunic Inc is 3.42%, while institutional ownership is 40.58%. The most recent insider transaction that took place on Jun 13 ’25, was worth 16,694. In this transaction Executive Chairman of this company bought 20,000 shares at a rate of $0.83, taking the stock ownership to the 36,032 shares. Before that another transaction happened on Jun 05 ’25, when Company’s President and COO bought 12,512 for $0.79, making the entire transaction worth $9,884. This insider now owns 12,512 shares in total.

Immunic Inc (IMUX) Latest Financial update

According to the Wall Street analysts, stocks earnings will be around 28.99% per share during the next fiscal year.

Immunic Inc (NASDAQ: IMUX) Trading Performance Indicators

Here are Immunic Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 0.74.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.98, a number that is poised to hit -0.17 in the next quarter and is forecasted to reach -0.57 in one year’s time.

Technical Analysis of Immunic Inc (IMUX)

Immunic Inc (NASDAQ: IMUX) saw its 5-day average volume 1.05 million, a negative change from its year-to-date volume of 1.27 million. As of the previous 9 days, the stock’s Stochastic %D was 63.27%.

During the past 100 days, Immunic Inc’s (IMUX) raw stochastic average was set at 24.70%, which indicates a significant decrease from 53.96% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 45.40% in the past 14 days, which was lower than the 94.91% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $0.8824, while its 200-day Moving Average is $1.1087. Nevertheless, the first resistance level for the watch stands at $0.7841 in the near term. At $0.8031, the stock is likely to face the second major resistance level. The third major resistance level sits at $0.8282. If the price goes on to break the first support level at $0.7400, it is likely to go to the next support level at $0.7149. The third support level lies at $0.6959 if the price breaches the second support level.

Immunic Inc (NASDAQ: IMUX) Key Stats

With a market capitalization of 73.30 million, the company has a total of 95,818K Shares Outstanding. Currently, annual sales are 0 K while annual income is -100,510 K. The company’s previous quarter sales were 0 K while its latest quarter income was -25,470 K.

News Daemon
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.